Fast Market Research

MAP Pharmaceuticals: PharmaVitae Report - New Market Research Report

New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research

 

Williamstown, MA -- (ReleaseWire) -- 04/16/2012 -- This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Report Scope:

- Gain insight into MAP Pharmaceuticals' strategic outlook
- Analyze company sales forecasts by product

Report Highlights

MAP's most advanced product candidate is Levadex (dihydroergotamine), an orally inhaled migraine therapy, which represents the main driver for the company. The New Drug Application for Levadex is currently under review by the FDA with an action date of March 26, 2012.

Reasons to Get this Report:

- Benchmark MAP Pharmaceuticals' performance against key rivals in the prescription pharmaceutical sector
- Assess how successful MAP Pharmaceuticals will be in obtaining marketing approval for its first product

View Full Report Details and Table of Contents

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- MAP Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011
- MAP Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
- MAP Pharmaceuticals, Inc. (MAPP) - Financial and Strategic SWOT Analysis Review
- Amylin Pharmaceuticals, Inc.: PharmaVitae Report
- King Pharmaceuticals, Inc - Strategy, SWOT, and Corporate Finance Report
- Endo Pharmaceuticals Holdings Inc. - Strategy, SWOT, and Corporate Finance Report
- Cubist Pharmaceuticals, Inc. - Strategy, SWOT, and Corporate Finance Report
- Watson Pharmaceuticals, Inc. - Strategy, SWOT, and Corporate Finance Report
- Progenics Pharmaceuticals, Inc. - Strategy, SWOT, and Corporate Finance Report
- Amylin Pharmaceuticals, Inc. - Strategy, SWOT, and Corporate Finance Report